Progress of epigenetics alterations and drug therapy of peripheral T-cell lymphoma

VernacularTitle:外周T细胞淋巴瘤的表观遗传学改变及药物研究进展
Author: Jiaqi BAI ¹ ; Zunmin ZHU
Author Information

1. 河南大学人民医院　河南省人民医院血液内科　河南省人民医院血液病研究所，郑州　450003
Keywords: Lymphoma, T-cell, peripheral; Follicular helper T cells; Epigenetics; Drug therapy
From: Journal of Leukemia & Lymphoma 2025;34(9):573-576
CountryChina
Language:Chinese
Abstract: Peripheral T-cell lymphoma (PTCL) is a subtype of non-Hodgkin lymphoma, which has a low incidence, high heterogeneity and poor prognosis; and its pathogenesis is still unclear. Mutations in epigenetic modifier genes are the most common mutations of PTCL, such as histone modification and DNA methylation, which play a key role in the development of follicular helper T-cell lymphomas. Novel epigenetically targeted agents have achieved significant clinical benefits in the treatment of follicular helper T cell phenotypic lymphomas, especially in combination therapy; and those agents may improve the prognosis of PTCL, especially in patients with relapsed or refractory PTCL. This article reviews epigenetic alterations in PTCL and the related advances in drug therapy.